Cases and Conversations™: Mineralocorticoid Receptor Antagonists in Patients With HF—Augmenting Current Guidelines with Emerging Evidence

Release Date: September 30, 2025

Expiration Date: September 30, 2026

Activity Overview

Heart failure (HF), a major challenge in cardiovascular medicine, presents significant morbidity and mortality despite advances in treatment. Mineralocorticoid receptor antagonists (MRAs) have emerged as a cornerstone of therapy, demonstrating substantial benefits in reducing hospitalization, improving survival, and enhancing quality of life in appropriately selected patients.

This program is designed to provide physicians with a comprehensive understanding of the role of MRAs in managing HF. Expert faculty will review the underlying pathophysiology of MR activation, discuss clinical evidence supporting both steroidal and nonsteroidal MRAs across the spectrum of HF phenotypes, and highlight practical strategies for patient selection, initiation, monitoring, and long-term management. Through interactive case discussions and evidence-based updates, participants will gain insights into optimizing MRA use in clinical practice, addressing challenges that include hyperkalemia and renal function, and integrating MRAs into guideline-directed medical therapy.

Target Audience

This educational activity is directed toward cardiologists, primary care physicians, nurse practitioners, physician assistants, and registered nurses who specialize in treating patients with HF.

Learning Objectives

Upon successful completion of this activity, you should be better prepared to:

• Summarize clinical characteristics of the steroidal and non-steroidal classes of mineralocorticoid receptor antagonists (MRAs)
• Analyze recent clinical trial efficacy and safety data for MRAs studied in patients with HFmrEF and/or HFpEF
• Integrate emerging evidence regarding the use of MRAs into the development of individualized guideline-directed treatment plans for appropriate patients with HFmrEF or HFpEF